首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Cell-penetrating conjugates of pentaglutamylated methotrexate as potential anticancer drugs against resistant tumor cells
【24h】

Cell-penetrating conjugates of pentaglutamylated methotrexate as potential anticancer drugs against resistant tumor cells

机译:五谷氨化甲氨蝶呤的穿透细胞的缀合物作为抗耐药肿瘤细胞的潜在抗癌药物

获取原文
获取原文并翻译 | 示例
           

摘要

The emerging resistance of tumor cells against methotrexate (MTX) is one of the major limitations of the MTX treatment of tumorous diseases. The disturbance in the polyglutamation which is a main step in the mechanism of methotrexate action is often the reason of the resistance. Delivery of polyglutamylated MTX into cells may evade the mechanisms that are responsible for drug resistance. In this study conjugates of methotrexate and its pentaglutamylated derivatives with cell-penetrating peptides penetratin and octaarginine - were investigated. The cellular-uptake and in vitro cytostatic activity of conjugates were examined on breast cancer cell cultures (MDA-MB-231 as resistant and MCF-7 as sensitive cell culture). These cell cultures showed very different behaviour towards the conjugates. Although the presence of pentaglutamyl moiety significantly decreased the internalisation of conjugates, some of them were significantly active in vitro. All of the conjugates were able to penetrate in some extent into both cell types, but only the conjugates of penetratin showed in vitro cytostatic activity. The most effective conjugates were the MTX-Glus-Penetratin(desMet) and MTX-Glu(5)-GFLG-Penetratin(desMet). The latter was effective on both cell cultures while the former was active only on the resistant tumor cells. Our results suggest that the translocation of polyglutamylated MTX may be a new way to treat sensitive and more importantly resistant tumors. While both penetratin and octaarginine peptides were successfully used to deliver several kinds of cargos earlier in our case the activity of penetratin conjugates was more pronounced. (C) 2016 Elsevier Masson SAS. All rights reserved.
机译:肿瘤细胞对甲氨蝶呤(MTX)的新兴耐药性是MTX治疗肿瘤疾病的主要限制之一。甲氨蝶呤作用机理中的主要步骤是多聚谷氨酸的紊乱,通常是产生抗药性的原因。将聚谷氨酰胺化的MTX传递到细胞中可能会逃避引起耐药性的机制。在这项研究中,研究了甲氨蝶呤及其五谷氨酰化衍生物与穿透细胞的肽渗透肽和八精氨酸的缀合物。在乳腺癌细胞培养物中检测了缀合物的细胞摄取和体外抑癌活性(MDA-MB-231为抗药性,MCF-7为敏感细胞培养物)。这些细胞培养物对缀合物表现出非常不同的行为。尽管五谷氨酰基部分的存在显着降低了缀合物的内在化,但其中一些在体外具有显着活性。所有的结合物都能在某种程度上渗透到两种细胞类型中,但是只有渗透肽的结合物显示出体外细胞抑制活性。最有效的缀合物是MTX-Glus-Penetratin(desMet)和MTX-Glu(5)-GFLG-Penetratin(desMet)。后者对两种细胞培养均有效,而前者仅对抗性肿瘤细胞有活性。我们的结果表明,聚谷氨酰胺化MTX的易位可能是治疗敏感且更重要的耐药性肿瘤的新方法。尽管在我们的案例中,渗透肽和八精氨酸肽都已成功地成功用于较早地递送多种货物,但渗透肽缀合物的活性更为明显。 (C)2016 Elsevier Masson SAS。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号